Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426

Plimack, Elizabeth R. and Rini, Brian I. and Stus, Viktor and Gafanov, Rustem and Waddell, Tom and Nosov, Dmitry and Pouliot, Frédéric and Soulieres, Denis and Melichar, Bohuslav and Vynnychenko, Ihor and Azevedo, Sergio Jobim and Borchiellini, Delphine and McDermott, Raymond S. and Bedke, Jens and Tamada, Satoshi and Yin, Lina and Chen, Mei and Molife, L. Rhoda and Atkins, Michael B. and Powles, Thomas (2020) Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. Journal of Clinical Oncology, Vol.38 (15supp). p. 5001. ISSN 1527-7755 (online, version of record) and 0732-183X (print)

Text Тези закордонні.pdf Download (275kB)

Abstract

The randomized, open-label, phase 3 KEYNOTE-426 study (NCT02853331) demonstrated that pembrolizumab (pembro) + axitinib (axi) significantly improved OS, PFS, and ORR vs sunitinib as first-line therapy for advanced RCC (aRCC) at the first pre-planned interim analysis (minimum study follow-up of 7 mo). Updated analyses are presented here.

Item Type:	Article
Additional Information:	DOI: 10.1200/JCO.2020.38.15_suppl.5001
Subjects:	Nephrology Oncology
Divisions:	Departments > Department of Urology
Depositing User:	Елена Шрамко
Date Deposited:	16 Sep 2020 10:04
Last Modified:	16 Sep 2020 10:04
URI:	http://repo.dma.dp.ua/id/eprint/5714

Actions (login required)

View Item